Belgian biotech BioSenic has suspended a phase 2b trial of ALLOB – a stem cell-derived therapy designed to accelerate bone fracture healing – after it was unable to show e
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh